Brief: SAB Biotherapeutics Announces Publication Of Nonclinical Data Demonstrating SAB-185 Has High Potency For Effectively Neutralizing Circulating And Emerging Sars-Cov-2 Variants
02/03/2022 14:22
March 2 (Reuters) - SAB Biotherapeutics Inc SABS.O :
* SAB BIOTHERAPEUTICS ANNOUNCES PUBLICATION OF NONCLINICAL
DATA
DEMONSTRATING SAB-185 HAS HIGH POTENCY FOR EFFECTIVELY
NEUTRALIZING CIRCULATING AND EMERGING SARS-COV-2 VARIANTS
Source text for Eikon: ID:nGNX47Pygr
Further company coverage: SABS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on SAB Biotherapeutics
See all newsSAB Biotherapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
SAB Biotherapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Ferrari, Hawkeye 360, Micron Technology
U.S. STOCKS ON THE MOVE-Vertex Pharma, U.S. Energy Corp, SoFi Technologies
U.S. STOCKS ON THE MOVE-InspireMD, MiniMed, SoFi Technologies